Tag

Retatrutide

All articles tagged with #retatrutide

health9 days ago•1 min saved

Unapproved Retatrutide Black Market Linked to Two Deaths

Eli Lilly’s experimental weight-loss drug retatrutide, which mimics three hunger hormones and offers up to 30% weight loss, has not yet received FDA approval. However, a black market for counterfeit versions has emerged, leading to at least two reported deaths this year. The FDA received reports of a 41-year-old woman dying of cardiac arrest and a 49-year-old patient dying after severe dehydration and cardiac arrest, both linked to unregulated sources. While causation is not proven, these incidents highlight the dangers of unapproved GLP-1 drugs, which often lack quality control and may contain incorrect dosages or other substances.

via Gizmodo|

#black-market #eli-lilly #fda

health-and-safety10 days ago•4 min saved

FDA Reports Two Deaths Linked to Illicit Retatrutide

The FDA received reports of two deaths linked to unapproved, bootleg versions of the experimental weight-loss drug retatrutide. While the agency has not verified the claims, Eli Lilly is pursuing legal action against sellers of counterfeit products, warning that contaminated or incorrect doses pose severe risks to patients.

via CBS News|

#consumer-safety #eli-lilly #fda

health20 days ago•4 min saved

Eli Lilly’s Retatrutide Sets New Weight-Loss Benchmarks in Phase 3 Trials

Eli Lilly’s experimental triple-agonist retatrutide achieved up to 25% weight loss in non-diabetic adults and 18.8% in those with type 2 diabetes in Phase 3 trials. The drug targets GLP-1, GIP, and glucagon, offering benefits beyond weight loss, including improved knee pain, sleep apnea, and blood sugar control, though gastrointestinal side effects remain common.

via ScienceAlert|

#eli-lilly #glp-1 #health

health-and-science21 days ago•3 min saved

Amylin and Triple-Agonist Trials Signal Next Wave in Obesity Treatment

Eli Lilly and Novo Nordisk are advancing next-generation obesity treatments targeting the amylin pathway and multiple hormone receptors. Lilly’s Phase 2 trial showed its amylin drug eloralintide, combined with tirzepatide, achieved 23.3% weight loss, though side effects caused higher discontinuation rates. Meanwhile, Lilly’s triple-agonist retatrutide reached a Phase 3 milestone, with 12mg doses yielding 18.8% weight loss and improved metabolic markers in diabetic patients. Novo is preparing to launch its amylin-based CagriSema next year. These developments aim to address patients who do not respond adequately to current GLP-1 therapies, expanding treatment options through multi-pathway approaches.

via CNBC|

#amylin #eli-lilly #health-and-science

health-and-science22 days ago•3 min saved

Eli Lilly Unveils Retatrutide and EloraTZP Data, Showcasing Massive Weight Loss and New Side Effect Profiles

Eli Lilly has released new Phase 3 data for its triple-agonist drug retatrutide, showing that even the lowest dose yields significant weight loss, while a new combination therapy, EloraTZP, demonstrates even greater efficacy but with higher dropout rates due to side effects.

via New York Post|

#eli-lilly #eloratzp #glp-1

healthcare22 days ago•0 min saved

Lilly's Retatrutide and EloraTZP Set New Weight-Loss Benchmarks at EASD

Eli Lilly reported that its experimental triple-agonist retatrutide caused an average weight loss of 49.6 pounds in patients with Type 2 diabetes, while a new combination therapy, EloraTZP, achieved up to 54.1 pounds of loss. Both drugs target multiple gut hormones to enhance satiety and metabolic control, with retatrutide expected to seek FDA approval by March 2027.

via USA Today|

#eli-lilly #eloratzp #glp-1

health22 days ago•1 min saved

Lilly's amylin-tirzepatide combo outperforms retatrutide in diabetes weight loss trials

Eli Lilly reported that its experimental combination therapy, eloraTZP, achieved an average weight loss of 23.3% in patients with obesity and type 2 diabetes, surpassing its own triple-agonist candidate retatrutide in that specific population. The Phase 2 trial, presented at the European Association for the Study of Diabetes in Milan, showed that the highest dose of the amylin and tirzepatide combo resulted in a 54.1-pound loss over 48 weeks. While efficacy was strong, discontinuation rates due to gastrointestinal side effects were higher than for individual components. Lilly plans to begin Phase 3 trials in the fourth quarter of 2026, aiming to optimize dosing to improve tolerability while maintaining efficacy.

via Fierce Biotech|

#eli-lilly #eloratzp #health

health22 days ago

Lilly’s amylin-tirzepatide combo and retatrutide set new benchmarks for weight loss

Eli Lilly has advanced two major obesity treatments: a new amylin-tirzepatide combination and the triple-agonist retatrutide. The combination therapy achieved up to 23.3% weight loss in a Phase 2 trial, while retatrutide reached up to 25% weight loss in Phase 3 trials for obesity and 23% for Type 2 diabetes. Both drugs target multiple gut hormones to enhance satiety and metabolic effects, positioning them as potential alternatives to existing GLP-1 therapies. Lilly plans to file for retatrutide approval early next year and advance the combination therapy to Phase 3 trials by late 2026.

via Endpoints News|

#eli-lilly #eloralintide #glp-1

health23 days ago•0 min saved

Lilly Unveils Retatrutide and EloraTZP Data at EASD, Signaling Next-Gen Obesity Strategy

Eli Lilly presented detailed phase 3 data for retatrutide and phase 2 results for the experimental combination EloraTZP at the European Association for the Study of Diabetes in Milan. Retatrutide, a triple-agonist, achieved 20.8% average weight loss at the top dose, while EloraTZP, combining amylin and tirzepatide, reached 23.3% weight loss. Lilly plans to file for retatrutide approval in early 2027 and advance EloraTZP to phase 3 trials by year-end.

via Fierce Biotech|

#eli-lilly #eloratzp #glp-1

health23 days ago•0 min saved

Eli Lilly’s Retatrutide Sets New Weight-Loss Records in Phase 3 Trials

Eli Lilly’s experimental triple-agonist drug retatrutide has demonstrated unprecedented weight-loss results in two major Phase 3 trials, with participants losing up to 25% of their body weight. The drug, which targets three gut hormones, also significantly improved blood sugar control and cardiometabolic markers, though it carries gastrointestinal side effects similar to existing GLP-1 medications.

via The Guardian|

#eli-lilly #glp-1 #health

health23 days ago•4 min saved

Eli Lilly’s Retatrutide Sets New Weight-Loss Records in Phase 3 Trials

Eli Lilly’s experimental triple-agonist retatrutide achieved record-breaking weight loss in two phase 3 trials, with participants losing up to 25% of body weight. The drug also improved cardiometabolic markers and resolved prediabetes in over 90% of cases, though it carries gastrointestinal side effects and lacks head-to-head comparisons with existing treatments.

via Ars Technica|

#eli-lilly #glp-1 #health

health23 days ago•396 min saved

Eli Lilly’s Retatrutide Sets New Weight Loss Records in Phase 3 Trials

Eli Lilly’s experimental triple-agonist drug, retatrutide, has demonstrated unprecedented weight loss in late-stage clinical trials. In a phase 3 study for patients with Type 2 diabetes, participants lost up to 23% of their body weight, while those with obesity but no diabetes lost up to 25%. The drug targets three hormones, including glucagon, to enhance metabolic effects beyond existing GLP-1 therapies. Lilly plans to file for FDA approval early next year, though unapproved versions are already circulating.

via NBC News|

#eli-lilly #glp-1-agonists #health

health1 month ago•8 min saved

Retatrutide leads in weight loss trials as microdosing debate intensifies

A new experimental drug, retatrutide, has shown superior weight loss results compared to Mounjaro in recent studies. Meanwhile, a surge in 'microdosing' GLP-1 medications like Wegovy and Zepbound has prompted medical experts to warn that lower doses yield significantly less weight loss and carry distinct side effects. While some patients seek smaller doses to mitigate gastrointestinal issues, clinical evidence remains limited, and doctors emphasize that standard titration schedules are necessary for optimal efficacy and safety.

via The Independent|

#glp-1-drugs #health #microdosing

health2 months ago•1 min saved

GLP-1 Drugs Show Surprising Benefits and Risks as New Triple-Agonist Enters Trials

GLP-1 weight-loss drugs, used for five years, are yielding unexpected benefits like reduced alcohol cravings and improved joint health, alongside risks such as muscle loss and vitamin deficiencies. A new triple-agonist drug, retatrutide, is in phase three trials, promising 25-30% weight loss comparable to bariatric surgery but with more side effects. Experts emphasize that these drugs are not a standalone solution and must be paired with lifestyle changes to preserve muscle and sustain results.

via WAFB|

#bariatric-surgery #glp-1-drugs #health

pharma2 months ago•34 min saved

Eli Lilly sues six firms to curb illegal retatrutide sales ahead of 2027 approval

Eli Lilly has filed six lawsuits against U.S. companies illegally selling its experimental obesity drug retatrutide. The drug is still in Phase 3 trials and lacks FDA approval, yet a black market has emerged. Lilly is suing compounding pharmacies, medical spas, and online vendors, citing safety risks and brand damage. The company has referred over 200 entities to regulators and flagged 14,000 online listings. Lilly plans to seek FDA approval for retatrutide in early 2027.

via BioPharma Dive|

#black-market #eli-lilly #fda